Overview
KTTA market data
Price History
KTTA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$13.01 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.22 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.28 – $2.06 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $19.5 · P/B 0.27 · P/S 26.84.
Company news
Pasithea Therapeutics To Present Phase I Dose-Escalation Study Of Safety, Pharmacokinetics Of PAS-004, Macrocyclic MEK Inhibitor, For Treatment Of MAPK Pathway Driven Advanced Solid Tumors At ESMO Congress 2026Benzinga · Jul 21, 2026, 11:20 AM
NOTICE TO DISREGARD -- Thea FoundationGlobenewswire Inc · Jul 2, 2026, 3:15 PM
Pasithea Therapeutics Announces Updated Interim Safety And Clinical Activity Data From Its Trial Evaluating PAS-004 In Patients With MAPK Pathway-Driven Advanced Solid Tumors; PAS-004 Has Been Well-Tolerated, With All Treatment-Related Adverse Events Being Grade 1 Or 2Benzinga · Jun 30, 2026, 11:10 AM
HC Wainwright & Co. Reiterates Buy on Pasithea Therapeutics, Maintains $3 Price TargetBenzinga · Jun 16, 2026, 3:45 PM
Pasithea Therapeutics Amends Clinical Study Protocol For Phase 1/1b Trial Of PAS-004 In Neurofibromatosis Type 1 Patients With Symptomatic Inoperable, Incompletely Resected, Or Recurrent Plexiform NeurofibromaBenzinga · Jun 16, 2026, 11:25 AM
Pasithea Therapeutics Announced It Will Participate As An Exhibitor In The Upcoming Children's Tumor Foundation 2026 Nf Conference, Held June 26-30, 2026, In Denver, ColoradoBenzinga · Jun 15, 2026, 11:25 AM
Pasithea Therapeutics Says FDA Grants Orphan Drug Designation To PAS-004 For Treatment Of Amyotrophic Lateral SclerosisBenzinga · Jun 2, 2026, 11:08 AM
Pasithea Therapeutics Corp. Receives FDA Orphan Drug Designation For MEK1/2 Inhibitor For Treatment Of Amyotrophic Lateral SclerosisBenzinga · May 29, 2026, 5:55 PM
Pasithea Therapeutics Q1 EPS $(0.12) Beats $(0.45) EstimateBenzinga · May 15, 2026, 10:22 PM